<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35343384</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV.</ArticleTitle><Pagination><StartPage>1145</StartPage><EndPage>1153</EndPage><MedlinePgn>1145-1153</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2059404</ELocationID><Abstract><AbstractText>Analysis of large-scale gene expression post vaccination can provide an overview of immune responses. We used transcriptional approaches to comprehensively analyze the innate immune response signatures elicited by protein subunit (PS) vaccine ZF2001 and an mRNA vaccine named RRV. A fine-grained time-dependent dissection of large-scale gene expression post immunization revealed that ZF001 induced MHC class II-related genes, including <i>cd74</i> and <i>H2-Aa</i>, more expeditiously than the RRV. Notably, the RRV induced MHC class I-related genes such as <i>Tap1</i>/<i>2</i>, <i>B2m,</i> and <i>H2-D1</i>/<i>K1</i>. At day 21 post immunization, the titres of binding and neutralization antibody (NAb) induced by both vaccines were comparable, which were accordant with the expression level of genes essential to BCR/TCR signalling transduction and B/T cells activation at day 7. However, compared to ZF2001, the early responses of RRV were more robust, including the activation of pattern recognition receptors (PRRs), expression of genes involved in RNA degradation, and transcription inhibition, which are directly related to anti-viral signals. This pattern also coincided with the induction of cytokines by the RRV. Generally, the transcriptomic patterns of two very different vaccines mapped here provide a framework for establishing correlates between the induction of genes and protection, which can be tailored for evoking specific and potent immune responses against SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Biological Products Co., Ltd., China National Biotec Group, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinghuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute of Biological Products Co., Ltd., China National Biotec Group, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Minhai Biotechnology Co., Ltd., Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xujia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd., China National Biotec Group, Changchun, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co., Ltd., China National Biotec Group, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changchun Institute of Biological Products Co., Ltd., China National Biotec Group, Changchun, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">protein subunit vaccine</Keyword><Keyword MajorTopicYN="N">transcriptome sequencing</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>28</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35343384</ArticleId><ArticleId IdType="pmc">PMC9037177</ArticleId><ArticleId IdType="doi">10.1080/22221751.2022.2059404</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Heathy Origination . COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines, 2021.</Citation></Reference><Reference><Citation>Science . Novavax&#x2019;s long-awaited COVID-19 vaccine authorizations offer an alternative to mRNA. Available from: https://www.science.org/content/article/novavax-s-long-awaited-covid-19-vaccine-authorizations-offer-alternative-mrna, 2021.</Citation></Reference><Reference><Citation>World Heathy Origination . WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int, 2021.</Citation></Reference><Reference><Citation>Clover Biopharmaceuticals . Clover&#x2019;s COVID-19 vaccine candidate demonstrates 79% efficacy against delta in global phase 2/3 SPECTRA trial dominated by variants of concern and interest. Available from: https://www.cloverbiopharma.com/news/83.html, 2021.</Citation></Reference><Reference><Citation>He Q, Mao Q, Zhang J, et al. . COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol. 2021;12:669339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071852</ArticleId><ArticleId IdType="pubmed">33912196</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, He Q, An C, et al. . Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect. 2021 Dec;10(1):1598&#x2013;1608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381941</ArticleId><ArticleId IdType="pubmed">34278956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Li Q, Wu J, et al. . Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infec. 2020 Dec;9(1):680&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Scott MKD, Hagan T, et al. . Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021 Aug;596(7872):410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgdorf S, Kautz A, Bohnert V, et al. . Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8T cell activation. Science. 2007 Apr 27;316(5824):612&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463291</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Yang K, Li R, et al. . mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci. 2020 Sep 9;21(18):6582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554980</ArticleId><ArticleId IdType="pubmed">32916818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolovska A, Hem SL, HogenEsch H.. Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants. Vaccine. 2007 Jun 6;25(23):4575&#x2013;4585.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzuto M, Gangloff M, Scherman D, et al. . Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers. J Control Release. 2017 Feb 10;247:182&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5312493</ArticleId><ArticleId IdType="pubmed">28040465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, You X, Wang X, et al. . Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2005191118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017939</ArticleId><ArticleId IdType="pubmed">33547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Linares-Fernandez S, Lacroix C, Exposito JY, et al. . Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med. 2020 Mar;26(3):311&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">31699497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen S, Thomsen AR.. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012 Mar;86(6):2900&#x2013;2910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302314</ArticleId><ArticleId IdType="pubmed">22258243</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke JM, Moon SL, Matheny T, et al. . RNase l reprograms translation by widespread mRNA turnover escaped by antiviral mRNAs. Mol Cell. 2019 Sep;75(6):1203&#x2013;1217.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754297</ArticleId><ArticleId IdType="pubmed">31494035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk A, Doener F, Zanzinger K, et al. . Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016 Jul 19;34(33):3882&#x2013;3893.</Citation><ArticleIdList><ArticleId IdType="pubmed">27269061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi C, Terpos E, Rosati M, et al. . Systemic IL-15, IFN-&#x3b3;, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 Aug 10;36(6):109504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299183</ArticleId><ArticleId IdType="pubmed">34352226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanova EN, Devlin JC, Buus TB, et al. . SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19. Preprint. medRxiv. 2021;2021.04.20.21255677.</Citation></Reference><Reference><Citation>Feng S, Phillips DJ, White T, et al. . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021 Nov;27(11):2032&#x2013;2040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott AB, et al. . 
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021. Available from: https://www.science.org/doi/epdf/10.11 26/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Li Y, Dai L, et al. . Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990482</ArticleId><ArticleId IdType="pubmed">33773111</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MA, Ganesan AP, Luckashenak N, et al. . Endogenous antigen processing drives the primary CD4+ T cell response to influenza. Nat Med. 2015 Oct;21(10):1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629989</ArticleId><ArticleId IdType="pubmed">26413780</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio F, Lambrecht BN, Janssens S.. Antigen presentation unfolded: identifying convergence points between the UPR and antigen presentation pathways. Curr Opin Immunol. 2018 Jun;52:100&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">29754111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjan K, Hedl M, Sinha S, et al. . Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response. J Clin Invest. 2021 Sep 1;131(17).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409591</ArticleId><ArticleId IdType="pubmed">34623328</ArticleId></ArticleIdList></Reference><Reference><Citation>Iavarone C, O'Hagan DT, Yu D, et al. . Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017 Sep;16(9):871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">28701102</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>